Venture capital investments in breakthrough biomedical technology companies.
learn more

The Catalio Strategy

Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by our Venture Partners, an elite group of world-renowned, serial scientist-entrepreneurs.  
learn more

Our Portfolio

We focus on biomedical technology companies developing next-generation drugs, devices and diagnostics, and work closely with each portfolio company to build and grow the business from inception to exit.
learn more

OUR TEAM

The Catalio team comprises a unique combination of investment professionals and world-renowned, serial scientist-entrepreneurs.  Together, we have a proven track record in starting up and spinning out category-defining businesses in the life sciences.
learn more

CONTACT

Our team works 24/7 in support of our partners, investors, and portfolio companies, so we are always happy to hear from you.
Reach out now

RECENT NEWS

@eGenesisBio, founded by Catalio Venture Partner & gene editing pioneer @geochurch is the newest addition to our portfolio! eGenesis uses cutting-edge gene editing technologies to grow organs for xenotransplantation. https://t.co/CYiGw3ucGf
Our portfolio company ⁦@SetPointMed⁩ has enrolled its first patient in a pivotal trial for its novel electroceutical therapy for rheumatoid arthritis. Catalio participated in SetPoint’s Series B, led by @NEA earlier this year! https://t.co/FMVJyP3eyo
Female founders get far less VC funding than men. Here’s a look at the numbers in Baltimore
March 2019
See More Tweets